- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1400 |
Product Name |
ADT1400-Mirikizumab Biosimilar-(IL23A)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-IL13a antibody, anti IL13a antibody, recombinant IL13a, IL13a antibody, anti-IL13a monoclonal antibody, IL13a antibodies, IL13a recombinant antibody, IL13a blocking antibody
|
|
Alias |
LY-3074828 |
Host |
CHO Cells |
Species |
Human |
Target |
IL23A |
Gene ID |
51561 |
Isotype |
IgG4 Kappa |
Size |
1mg, 5mg |
Research Area |
Immunology |
CAS Number |
1884201-71-1 |
Product Description |
Mirikizumab (INN, development code LY3074828) is a human monoclonal antibody designed for the treatment of psoriasis. This drug was developed by Eli Lilly and Co. As of 2018, mirikizumab is undergoing Phase III trials. |
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Cua, D. J., et al. (2003). “Interleukin-23 as a therapeutic target in autoimmune disease.” Nature Reviews Drug Discovery, 2(1), 1-12.
2. McGeachy, M. J., et al. (2007). “The role of IL-23 in the development of Th17 cells.” Nature Reviews Immunology, 7(9), 657-667.
3. Korn, T., et al. (2009). “IL-23 and IL-17 in the pathogenesis of autoimmune disease.” Nature Reviews Immunology, 9(9), 681-693.
|